First quarter 2024 results

First quarter 2024 results were reviewed by management during a conference call with the financial community on April 25th. The presentation was followed by a Q&A session.

14:30 - 16:00 CET (8:30am – 10am EST)

Featuring

Paul Hudson

Paul Hudson

Chief Executive Officer

François Roger

François Roger

Chief Financial Officer

Houman Ashrafian

Houman Ashrafian

Head of Research and Development

Highlights

Paul Hudson comments on Q1 2024 results

We are off to an excellent start in 2024, delivering on our strategic priorities and a transformation of our portfolio of medicines and vaccines to become a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth.
Paul Hudson

Paul Hudson

Chief Executive Officer

Downloads

Presentation

Press release

Q1 2024 Income statements

Q1 2024 net sales by GBU, franchise, geographic region and product

R&D appendix

Infographic (accessible version)

Q1 2024 Memorandum for modelling purposes

Contact

Investor Relations

investor.relations@sanofi.com

More contact information